Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation operates in the immune medicine industry, leveraging the adaptive immune system to diagnose and treat diseases. The company's core business model involves applying proprietary technologies to sequence the genetic code of a patient's immune system, understand disease detection, and use these insights to develop and commercialize clinical products and services. Revenue is generated through diagnostic and research services, with a mix of recurring and transactional income derived from clinical customers, biopharmaceutical partners, and academic institutions. The total addressable market for the MRD business is estimated at approximately $6.2 billion ⁴, with about $5.3 billion ⁵ from clinical testing.

The company is structured around two main business segments: the MRD business and the Immune Medicine (IM) business. The MRD business focuses on minimal residual disease (MRD) assessment in lymphoid malignancies using its clonoSEQ assay. This includes the clonoSEQ clinical diagnostic test for clinicians and the clonoSEQ assay for biopharmaceutical partners to aid drug development. clonoSEQ is the first FDA-authorized test for MRD detection and monitoring in multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL), and is also available as a CLIA-validated laboratory developed test (LDT) for other lymphoid cancers like diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). The IM business leverages the company's ability to sequence, map, pair, and characterize T-cell receptors (TCRs) and B-cell receptors (BCRs) at scale. This segment offers immune receptor sequencing, licensing of proprietary data, TCR-antigen prediction models, and target discovery capabilities, with proprietary datasets including over 100,000 ⁶ signatures of cancer and autoimmune disease and more than 5,000,000 ⁷ matches of TCRs to disease-related antigens.

For the fiscal year ended December 31, 2025, total revenue was $276.976 million ⁸, an increase from $178.957 million ⁹ in 2024. Gross profit, calculated as revenue less cost of revenue, was $205.617 million ¹⁰ in 2025, compared to $106.877 million ¹¹ in 2024. The gross margin percentage was 74.2% ¹² in 2025, up from 59.7% ¹³ in 2024. Operating loss was $57.123 million ¹⁴ in 2025, a significant improvement from an operating loss of $162.549 million ¹⁵ in 2024. Net loss attributable to Adaptive Biotechnologies Corporation was $59.499 million ¹⁶ in 2025, compared to $159.492 million ¹⁷ in 2024. Diluted EPS was $(0.39) ¹⁸ in 2025, improving from $(1.08) ¹⁹ in 2024. Net cash used in operating activities was $45.986 million ²⁰ in 2025, a reduction from $95.212 million ²¹ in 2024. As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $227.2 million ²², excluding $13.1 million ²³ of cash held by Digital Biotechnologies, Inc. The total revenue interest liability, net, was $131.208 million ²⁴ as of December 31, 2025, comprising a current portion of $4.642 million ²⁵ and a long-term portion of $126.566 million ²⁶.

Year-over-year, total revenue increased by $98.019 million ²⁷, or 55% ²⁸. MRD revenue grew by $66.805 million ²⁹, or 46% ³⁰, primarily due to a $52.0 million ³¹ increase in revenue from clinical customers and a $7.0 million ³² increase from regulatory milestones. clonoSEQ test volume increased by 39% ³³ to 105,587 ³⁴ tests delivered in 2025. Immune Medicine revenue increased by $31.214 million ³⁵, or 93% ³⁶, largely driven by a $27.8 million ³⁷ increase from the Genentech Agreement due to its termination and subsequent deferred revenue recognition. Cost of revenue decreased by $0.721 million ³⁸, or 1% ³⁹, primarily due to reductions in inventory write-offs and assay costs, and lower labor and overhead. Research and development expenses decreased by $9.184 million ⁴⁰, or 9% ⁴¹, mainly from reduced personnel costs and decreased investments in drug discovery. Sales and marketing expenses increased by $9.812 million ⁴², or 12% ⁴³, driven by higher personnel costs, consulting, and computer/software expenses. General and administrative expenses saw a slight decrease of $0.105 million ⁴⁴.

During 2025, the company achieved several operational milestones. Payor coverage for clonoSEQ expanded to over 300 million ⁴⁵ lives in ALL and MM, over 270 million ⁴⁶ lives in CLL, and over 90 million ⁴⁷ lives in DLBCL, with new Medicare coverage for recurrence monitoring in MCL. clonoSEQ MRD testing was enabled in 173 ⁴⁸ sites on the Epic System Corporation's EMR system and 113 ⁴⁹ customer sites on Flatiron Health, Inc.'s OncoEMR. The clonoSEQ assay was utilized in more than 180 ⁵⁰ active trials by over 40 ⁵¹ biopharmaceutical partners. In December 2025, the company entered into two non-exclusive agreements with Pfizer Inc. to leverage its TCR discovery platform for therapeutic research in rheumatoid arthritis and broader immunology applications. The amount of paired TCRs to antigens increased from over two million to over five million ⁵², spanning over 20,000 ⁵³ antigens and nearly 50 ⁵⁴ HLA types. The company also operationalized NovaSeq X Plus sequencers for clonoSEQ clinical testing in the second half of 2025. The worldwide collaboration and license agreement with Genentech, Inc. was terminated on August 13, 2025, effective February 9, 2026, leading to the recognition of remaining deferred revenue.

The company anticipates its MRD revenue to increase in both the short and long term, driven by continued growth in clinical testing volume through enhanced penetration in existing patient populations, expansion into new patient populations, and optimized payor coverage. However, MRD revenue may fluctuate period-to-period due to the uncertain timing of biopharmaceutical customer sample receipts, which impacts product and service delivery, the recognition of regulatory milestone payments from biopharmaceutical customers, and changes in estimates of clinical revenue reimbursement rates. Conversely, Immune Medicine revenue is expected to decrease in the short term following the termination of the Genentech Agreement. This segment's revenue may also fluctuate due to the timing of customer sample receipts from biopharmaceutical partners and the potential recognition of milestones under target discovery agreements.

The company plans to utilize its existing cash, cash equivalents, and marketable securities primarily to fund commercial and assay development initiatives for clonoSEQ, continued research and development initiatives related to mapping TCRs to antigens, and the advancement of its target discovery capabilities. The company believes its current cash, cash equivalents, and marketable securities of $227.2 million ⁵⁵ (excluding $13.1 million ⁵⁶ of cash held by Digital Biotechnologies, Inc.) will be sufficient to fund operating expenses and capital expenditure requirements for at least the next 12 months. The company may consider raising additional capital in the future to expand its business, pursue strategic investments, or take advantage of financing opportunities.

The company expects cost of revenue to moderately increase in the short term and to increase in absolute dollars in the long term as sample testing volume grows. However, the cost per sample is projected to decrease over the long term due to anticipated efficiencies from improved utilization of laboratory capacity, automation, and other value engineering initiatives. Research and development expenses are expected to moderately decrease in the short term and to decrease as a percentage of revenue in the long term, though period-to-period fluctuations may occur based on the timing and extent of development and commercialization efforts. Sales and marketing expenses are expected to increase in the short term in absolute dollars as marketing activities intensify to drive awareness and adoption of products and services, but are expected to decrease as a percentage of revenue in the long term. General and administrative expenses are expected to moderately increase in the short term and to decrease as a percentage of revenue in the long term.

The company has a three-year, $17.5 million ⁵⁷ commitment for certain cloud services, with $11.3 million ⁵⁸ remaining as of December 31, 2025. It also has minimum commitments for laboratory material suppliers, generally fulfilled within one year, and additional software and service license commitments, generally fulfilled within one to three years.

The company faces significant risks, including the inability to achieve and maintain profitability due to substantial net losses since inception, with a net loss of $59.499 million ⁵⁹ in 2025 and an accumulated deficit of $1.4 billion ⁶⁰. Market acceptance and adoption of products and services, including clonoSEQ, are uncertain, particularly regarding payor coverage and adequate reimbursement, which could negatively affect commercial success. Operational risks include reliance on a limited number of single suppliers for laboratory equipment and materials, which could lead to significant costs and delays if supply is interrupted. Errors or defects in products or services could harm reputation and expose the company to product liability claims. The success of leveraging TCR-antigen binding data for new products and services is uncertain, and collaborations may fail or not yield expected monetary benefits. Clinical trials for future products may face unforeseen events, delays, or failures, impacting regulatory approval and commercialization. The company's ability to manage workforce expansion, commercial infrastructure, and laboratory operations to meet demand fluctuations is critical. Competition in the rapidly advancing biotechnology and pharmaceutical industries is intense, with many competitors possessing greater resources. Regulatory risks are substantial, including changes in laws, potential loss of licenses or certifications, and the FDA's evolving stance on LDTs, which could subject operations to more significant requirements. Violations of healthcare fraud and abuse laws, false claims laws, and health information privacy and security regulations (such as HIPAA, HITECH, GDPR, and state-specific laws like the Washington state My Health My Data Act, California Consumer Privacy Act, and Colorado Privacy Act) could result in significant liability, fines, and reputational harm. Cybersecurity breaches and the inherent risks of using artificial intelligence and machine learning also pose threats to data integrity and business operations. Intellectual property protection is crucial, and challenges to patents, trade secrets, or the inability to obtain new patents could diminish competitive advantage. The revenue interest purchase agreement with OrbiMed Royalty & Credit Opportunities IV, LP, which requires a five percent ⁶¹ payment of quarterly GAAP revenue ⁶² and has a return cap of 165% ⁶³ to 175% ⁶⁴ of the Purchaser Payment, could limit cash flow and expose the company to financial risks.

Management emphasizes its commitment to advancing immune medicine by decoding the adaptive immune system to transform disease diagnosis and treatment. They highlight the company's proprietary technologies and dynamic clinical immunomics database, underpinned by computational biology and machine learning, as core to developing tailored clinical products and services. Management reported 2025 revenue of $277.0 million ⁶⁵, an increase from $179.0 million ⁶⁶ in 2024, primarily driven by the MRD business, which grew by $66.8 million ⁶⁷. Net cash used in operations decreased by 52% ⁶⁸ to $46.0 million ⁶⁹ in 2025 from $95.2 million ⁷⁰ in 2024. As of December 31, 2025, cash, cash equivalents, and marketable securities stood at $227.2 million ⁷¹, excluding $13.1 million ⁷² held by Digital Biotechnologies, Inc. Management believes the company is on a path to profitability, focusing on gaining operating leverage. Strategic priorities include increasing clonoSEQ clinical testing volume through enhanced penetration in existing patient populations, expanding into new patient populations, and optimizing payor coverage. They also prioritize leveraging the immune medicine platform to sequence, map, pair, and characterize TCRs and BCRs at scale to drive opportunities in cancer and autoimmune disorders, including immune receptor sequencing, data licensing, TCR-antigen prediction models, and target discovery capabilities.